Reliable Supplier

CSL Biotherapies is one of the few providers of flu vaccine in the world today, which is a role that we take seriously.

Our 40-Year Track Record in Vaccines Says It All...

Consider: For each of the past 40 years, we have brought a consistently high-quality flu vaccine to market, despite considerable global challenges.

We are committed to this area of medicine. You can have complete confidence in our ability to produce quality vaccines and deliver them reliably.

Afluria^® Influenza Virus Vaccine Means Quality

To assure consistent quality of our vaccine, we tightly control every step of our manufacturing process and supply chain. This includes:

Close monitoring of egg production
Skillful seed development
Stringent control of individual batch quality in compliance with applicable regulatory guidelines
Distribution of product that is temperature and environment controlled

Production of Vaccine

Afluria^® is manufactured by CSL Limited in dedicated production facilities in Melbourne, Australia, and Marburg, Germany. The manufacturing facilities are maintained at the highest standard to produce this quality vaccine. They are subject to regular inspections by regulatory agencies, including the United States Food and Drug Administration (FDA).

At CSL Biotherapies, delivering vaccines is our mission, protecting life our passion.

Important Safety Information

Afluria^® is indicated for active immunization of persons 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria^®; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria^®.

Afluria^® should not be administered to individuals with hypersensitivity to eggs or chicken protein or other components of Afluria^®, or to anyone who has had a life-threatening reaction to previous influenza vaccination. The most common injection-site adverse reactions were tenderness, pain, redness, and swelling. The most common systemic adverse reactions were headache, malaise, and muscle aches.

Vaccination with Afluria^® may not protect all individuals. Immunocompromised persons may have a diminished immune response. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Afluria^® should be based on careful consideration of the potential benefits and risks.

Click here for full PRESCRIBING INFORMATION.

Reliable Supplier

Afluria® Influenza Virus Vaccine Means Quality

Production of Vaccine

Afluria^® Influenza Virus Vaccine Means Quality